B.Riley FBR analyst David Buck reiterated a Buy rating on Shire on December 4 and set a price target of $200. The company’s shares closed yesterday at $178.13, close to its 52-week high of $182.47.
“We reiterate our Buy rating for Shire ADS with our 12-month price target of $200 per share. We update our earnings model to reflect 3Q18 results plus updated Shire 2018 guidance items including total revenues of $15.3B-$15.8B and non-GAAP (adjusted) EPS of $14.77 to $15.37. Divestiture of the oncology business subtracts $100M in revenues and $0.13 in non-GAAP EPS from guidance. For 2018, we lower our adjusted EPS forecast from $15.30 to $15.15 and for 2019E we lower our adjusted EPS forecast from $17.50 to $17.20. Out-years for Shire stand-alone likewise have similar reductions. The key event for Shire, however, is a pending shareholder vote to approve the transaction by Takeda shareholders and Shire shareholders, both on December 5th. We expect both Takeda and Shire holders to approve the transaction.”
According to TipRanks.com, Buck is a 3-star analyst with an average return of 2.6% and a 44.6% success rate. Buck covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Supernus Pharmaceuticals, and Amag Pharmaceuticals.
Shire has an analyst consensus of Strong Buy, with a price target consensus of $194.50.
Aquestive Therapeutics Inc (AQST)
In a report issued on December 5, Liana Moussatos from Wedbush reiterated a Buy rating on Aquestive Therapeutics Inc, with a price target of $30. The company’s shares closed yesterday at $8.75, close to its 52-week low of $7.47.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -9.3% and a 34.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Liquidia Technologies Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aquestive Therapeutics Inc with a $28.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.